Literature DB >> 8242548

Combination chemotherapy in adult desmoid tumors.

S R Patel1, H L Evans, R S Benjamin.   

Abstract

BACKGROUND: Desmoid tumors are locally aggressive tumors, with no metastatic potential, that generally are amenable to local treatments, such as surgery and radiation therapy. Systemic therapy is considered for selected cases that are not amenable to local treatment.
METHODS: The authors reviewed their experience with chemotherapy in desmoid tumors. A patient population was identified through a search of the data base maintained by the Department of Patient Studies.
RESULTS: Between January 1971 and December 1991, 180 patients with a histologically confirmed diagnosis of desmoid tumor were seen at the authors' institution. Twelve patients (8 male and 4 female patients; age range, 16-66 years; median age, 29 years) received chemotherapy. Eleven patients received doxorubicin (60-90 mg/m2) plus dacarbazine (750-1000 mg/m2)-based regimens for a median of 5 cycles (2-10 cycles). Six of the nine patients who could be evaluated for response had an objective response (two complete responses and four partial responses), one patient had a minor response, and two patients had stable disease. Two other patients treated in the early 1970s could not be evaluated objectively because of lack of modern imaging; however, they were reported to have "responses" that enabled resection of axillary and pelvic disease. All four patients with Gardner syndrome experienced disease response. One of these four patients had a complete response twice with doxorubicin-based chemotherapy and eventually died with an ejection fraction of 0.22. Five patients are alive with no evidence of disease (NED), four are alive with disease, and two are lost to follow-up after having an NED status at their last visit.
CONCLUSION: The authors conclude that desmoid tumors in adults are responsive to chemotherapy, and such treatment should be considered before embarking on radical treatment to avoid obvious functional consequences and delayed complications.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242548     DOI: 10.1002/1097-0142(19931201)72:11<3244::aid-cncr2820721118>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  Extra-abdominal fibromatosis (desmoid tumor) arising in the infratemporal fossa: a case report.

Authors:  M Corsten; P Donald; J Boggan; A Gadre; R Gandour-Edwards; W Nemzek
Journal:  Skull Base Surg       Date:  1998

Review 2.  Mesenteric Fibromatosis Mimicking Metastasis: A Case Report and Review of Literature.

Authors:  Saikat Das; J Subhashini; Rajesh Isiah; Susy Kurian
Journal:  J Gastrointest Cancer       Date:  2012-09

3.  Multifocal extra-abdominal desmoid tumor--diagnostic and therapeutic problems.

Authors:  F Maurer; F Horst; C Pfannenberg; M Wehrmann
Journal:  Arch Orthop Trauma Surg       Date:  1996       Impact factor: 3.067

4.  Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.

Authors:  Xin Liu; Huijie Wang; Xianghua Wu; Xiaonan Hong; Zhiguo Luo
Journal:  Invest New Drugs       Date:  2017-11-23       Impact factor: 3.850

5.  Desmoid tumour in familial adenomatous polyposis patients: responses to treatments.

Authors:  Thibault Desurmont; Jérémie H Lefèvre; Conor Shields; Chrystelle Colas; Emmanuel Tiret; Yann Parc
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

6.  Activity of Sorafenib against desmoid tumor/deep fibromatosis.

Authors:  Mrinal M Gounder; Robert A Lefkowitz; Mary Louise Keohan; David R D'Adamo; Meera Hameed; Cristina R Antonescu; Samuel Singer; Katherine Stout; Linda Ahn; Robert G Maki
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

7.  Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies.

Authors:  Andrew J Bishop; Jace P Landry; Christina L Roland; Ravin Ratan; Barry W Feig; Bryan S Moon; Maria A Zarzour; Wei-Lien Wang; Alexander J Lazar; Valerae O Lewis; Keila E Torres; B Ashleigh Guadagnolo
Journal:  Cancer       Date:  2020-04-28       Impact factor: 6.860

Review 8.  Desmoid-Type Fibromatosis: Who, When, and How to Treat.

Authors:  Javier Martínez Trufero; Isabel Pajares Bernad; Irene Torres Ramón; Jorge Hernando Cubero; Roberto Pazo Cid
Journal:  Curr Treat Options Oncol       Date:  2017-05

9.  A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.

Authors:  Jae-Cheol Jo; Yong Sang Hong; Kyu-Pyo Kim; Jae-Lyun Lee; Jeeyun Lee; Young Suk Park; Sun Young Kim; Jin-Sook Ryu; Jong-Seok Lee; Tae Won Kim
Journal:  Invest New Drugs       Date:  2014-01-16       Impact factor: 3.850

10.  Desmoid tumors of the abdominal wall: A case report.

Authors:  Marcus Overhaus; Pan Decker; Hans Peter Fischer; Hans Jochen Textor; Andreas Hirner
Journal:  World J Surg Oncol       Date:  2003-07-09       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.